Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06745908 · ClinicalTrials.gov registry record · Phase 3
ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
A Phase 3 study of NSCLC Stage IV, sponsored by ImmunityBio.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 460
- Enrollment target
- 17
- Study locations
NCT06745908 is a Phase 3 study of NSCLC Stage IV that is actively recruiting participants, run by ImmunityBio. The registered enrollment target is 460 participants, above the 46-participant average among 6 other NSCLC Stage IV trials with a reported enrollment target (900% higher). The trial reports 17 study locations across 9 states.
The verdict
NCT06745908, a Phase 3 study of NSCLC Stage IV, is actively recruiting participants, sponsored by ImmunityBio.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 460 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a randomized, open-label, phase 3 clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (experimental arm) versus docetaxel monotherapy (control arm). Enrolled participants will be randomized 2:1 to treatment in the experimental arm or the control arm. Participant randomization will be stratified by geographical region (North America vs Europe vs ASIA vs Other), NSCLC histology (squamous vs nonsquamous), and actionable genomic alteration (AGA); (epidermal growth factor receptor \[EGFR\]/anaplastic lymphoma kinase \[ALK\] vs OTHER AGA vs No AGA).
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Tislelizumab
- DRUG N-803
Study Locations (17)
California
- Chan Soon-Shiong Institute for Medicine - El Segundo
- MemorialCare - Orange Coast Medical Center - Fountain Valley
- OPN Healthcare INC - Glendale
- OPN Healthcare INC/ Cancer and Blood Specialty Clinic - Los Alamitos
Florida
- Holy Cross Hospital - Fort Lauderdale
- The Oncology Institute of Hope and Innovation - Fort Lauderdale
- Moffit Cancer Center - Tampa
Ohio
- University of Cincinnati Medical Center - Cincinnati
- University Hospitals Cleveland Medical Center - Cleveland
Tennessee
- Tennessee Oncology - Nashville
- Vanderbilt - Ingram Cancer Center - Nashville
Virginia
- Virginia Cancer Specialists - Fairfax
- Virginia Commonwealth University - Richmond
Arkansas
- Highlands Oncology Group - Springdale
Georgia
- Emory University - Winship Cancer Institute - Atlanta
Missouri
- Barnes-Jewish Hospital - Siteman Cancer Center (Washington University - St. Louis) - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2029-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06745908
The ClinicalTrials.gov registry entry for NCT06745908 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 460 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 46-participant average among 6 other NSCLC Stage IV trials with a reported enrollment target (900% higher). The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with NSCLC Stage IV appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.
NCT06745908 reports 17 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT06745908 about?
NCT06745908 is a clinical study titled "ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer". This is a randomized, open-label, phase 3 clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (experimental arm) versus docetaxel monotherapy (control arm). Enrolled participants will be randomized 2:1 to treatment in the experimental arm or the control arm. Pa...
What is the current status of trial NCT06745908?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 460 participants. The study started on 2025-10-01. Estimated completion is 2029-01.
What conditions does trial NCT06745908 study?
This clinical trial studies the following conditions: NSCLC Stage IV.
What interventions are being tested in trial NCT06745908?
The interventions under investigation include: Docetaxel (DRUG), Tislelizumab (DRUG), N-803 (DRUG).
Who is sponsoring clinical trial NCT06745908?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06745908 being conducted?
This trial has 17 study locations across Arkansas, California, Florida, Georgia, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NSCLC Stage IV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
RECRUITING · Phase 1
-
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
RECRUITING
-
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
RECRUITING · Phase 1
-
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Plasma-Adapted First-Line Pembro In NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.